Recently, Wecare Probiotics Co., Ltd. has received a new round of financing. This round of financing was jointly invested by Suzhou Venture Capital (SDIC), China Merchants Capital, and SDIC Innovation.

Read the original text

HSGD (Suzhou) Biomedical Technology Co., Ltd. has recently completed a new round of financing, led by Guohai Innovation Capital with participation from the Suzhou Industrial Park Science and Technology Innovation Fund. The funds will mainly be used to advance the scaled production and commercialization of the company’s glaucoma intraocular pressure monitoring product, Haisiwei®. HSGD is gradually becoming a full-scenario solution provider centered on glaucoma patients, integrating preoperative screening, intraoperative treatment, and postoperative intraocular pressure management.

Read the original text

Hepatobiliary duct stone disease is a common biliary condition in China, characterized by complex conditions, treatment difficulties, and multiple complications. In response to the severe challenges posed by hepatobiliary duct stone disease, Innovatech has introduced a cholangioscope that combines standard and ultra-thin cholangioscopes along with related consumables, aiming to provide unprecedented precision diagnosis and treatment solutions for both doctors and patients.

Read the original text

Betapharm's BeiRuisheng® Roxadustat Capsules Approved: National Negotiation Product, Dual-Channel Directory Product, Deemed to Have Passed the Consistency Evaluation. Roxadustat Capsules are indicated for anemia caused by chronic kidney disease (CKD), including both dialysis and non-dialysis patients. Roxadustat is the world's first HIF-PHI (hypoxia-inducible factor prolyl hydroxylase inhibitor) drug approved for marketing by the China National Medical Products Administration, offering a novel treatment option for patients with renal anemia. It is recommended by authoritative guidelines as a first-line new treatment for anemia in chronic kidney disease.

Read the original text

On July 19, Hengmei Health's "Intelligent Health Future New Food Space" 2024 New Product Launch Conference was successfully held in Hangzhou. The event unveiled eight series of significant new products featuring new technologies, new formulations, and new formats. Professor Fengqin Feng from Zhejiang University, Professor Wei Zhao from Jiangnan University, Chen Zhenrong, Director of Greater China at Frost & Sullivan, and Zheng Yadan, CEO of Hengmei Group, shared professional insights on the development of nutrition and health foods.

Read the Original Text

On June 28, Qitan Tech's self-developed universal reagent for sequencing reactions successfully obtained the Class I In Vitro Diagnostic Reagent Filing Certificate issued by the Chengdu Market Supervision Administration, with the filing certificate number: CRMD Filing 20240058, and simultaneously acquired the Class I medical device production filing qualification.

Read the Original Text

On the morning of July 27, 2024, Beijing Zhiprotein Biopharmaceutical Technology Co., Ltd. successfully held the "Phase II Clinical Study: A Randomized, Double-blind, Placebo-controlled Trial Evaluating the Efficacy, Safety, and Pharmacokinetic Characteristics of ZT002 Injection in Overweight or Obese Subjects" National Investigators' Meeting in Beijing, China.

Read the Original Text

Recently, another invention patent of K-Clip® Transcatheter Tricuspid Annuloplasty System from Shanghai Huihe Medical Technology Co., Ltd. has been successfully granted authorization by the United States Patent and Trademark Office. This achievement marks yet another successful overseas authorization following the granting of core invention patents for the K-Clip® product in the United States, Canada, and the European Union, further strengthening Huihe Medical's patent protection system for its products abroad.

Read the Original Text

On July 1, a user served by Maixin Yunyao successfully completed the first administration of the Alzheimer's disease (AD) innovative drug Le Yibao® at a hospital in Nanjing, marking the first Le Yibao® treatment assisted by Maixin Health.

Read the original text

On July 8, 2024, Tongyuan Kang Medicine announced that its independently developed new-generation oral, highly efficient, and highly selective small-molecule YAP/TEAD inhibitor, TYK-01054, received official approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) to commence clinical trials. Previously, TYK-00540 had received a Study May Proceed Letter (IND 169813) from the U.S. Food and Drug Administration (FDA). Currently, there are no approved YAP/TEAD inhibitors on the market globally, and drugs targeting this pathway hold significant potential for broad clinical applications.

Read the original text

Recently, the new product Tiotropium Bromide Powder for Inhalation independently developed by Changfeng Pharmaceutical Co., Ltd. has obtained the clinical tacit approval from the National Medical Products Administration (NMPA). This product is mainly used for the treatment of chronic obstructive pulmonary disease (COPD), and can also be used for maintenance therapy of chronic bronchitis and emphysema with breathing difficulties, as well as the prevention of acute exacerbations.

Read the Original Text

Recently, HC Pharma (688302.SH) announced that its investigational drug HP518 has been granted "Fast Track Designation" (FTD) by the U.S. Food and Drug Administration (FDA) for the treatment of androgen receptor (AR)-positive triple-negative breast cancer. Currently, no products targeting the same mechanism have been approved for marketing in or outside China.

Read the Original Text

Recently, Yino Pharmaceuticals announced that the Phase II clinical trial for weight loss using Yisupagluride α Injection was successfully completed with all patients enrolled by early July, marking a significant milestone in the clinical research! This study (chinadrugtrials.org, CTR20240801) is a clinical trial of "Yisupagluride α Injection in overweight and obese subjects who have not achieved satisfactory weight control through diet and exercise interventions." Approved by the National Medical Products Administration, the study is led by Professor Jia Weiping, an academician of the Chinese Academy of Engineering and a professor at the Sixth People's Hospital affiliated with Shanghai Jiao Tong University School of Medicine.

Read the Original Text

From July 2 to 3, 2024, the Third Single-Cell Spatiotemporal Omics and Applications Forum & Symposium on Spatial Omics Technologies and Methods, hosted by the School of Public Health at Xi'an Jiaotong University, the Single-Cell Omics and Health Research Center of the School of Public Health at Xi'an Jiaotong University, and the Trace Elements Branch of the Shaanxi Medical Association, was grandly held in Xi'an, Shaanxi. As a globally leading provider of comprehensive spatial omics solutions, Sailu Healthcare was invited to participate in this conference and was recognized as a "Strategic Partner of the Single-Cell Omics Research Institute."

In this strategic cooperation, CelluGen will provide its self-developed high-throughput sequencing platform and high-resolution spatial transcriptomics platform. By integrating its proprietary high-throughput sequencing and super-resolution fluorescence imaging technologies, subcellular resolution analysis can be achieved, enabling more effective research in areas such as tissue cell function, intercellular microenvironment interactions, and disease pathology.

Read the Original Text

On July 19, 2024, Vice President Chen Qingshan of the College of Agriculture at Northeast Agricultural University led a delegation to visit Chengdu Hanchen Guangyi Technology Co., Ltd. for research and exchange. Representatives from both parties signed a strategic cooperation agreement for the "Smart Breeding Joint Center" on the research and application of smart breeding.

Read the original text